Scarica l'app Stockscreener
6.74
5.81%
0.37
Dopo l'orario di chiusura:
6.41
-0.33
-4.90%
Precedente Chiudi:
$6.37
Aprire:
$6.45
Volume 24 ore:
30,390
Relative Volume:
0.19
Capitalizzazione di mercato:
$130.22M
Reddito:
-
Utile/perdita netta:
$-22.38M
Rapporto P/E:
-4.7801
EPS:
-1.41
Flusso di cassa netto:
$-15.54M
1 W Prestazione:
+4.98%
1M Prestazione:
+31.13%
6M Prestazione:
+3.69%
1 anno Prestazione:
-8.42%
Intervallo 1D:
$6.3333
$6.74
Intervallo di 1 settimana:
$6.12
$7.15
Portata 52W:
$4.44
$12.10
Nuvectis Pharma Inc Stock (NVCT) Company Profile
Nome
Nuvectis Pharma Inc
Settore
Industria
Telefono
360-837-7232
Indirizzo
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Confronta NVCT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NVCT
Nuvectis Pharma Inc
|
6.74 | 130.22M | 0 | -22.38M | -15.54M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 112.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 75.06B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.45B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.75B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 28.98B | 3.30B | -501.07M | 1.03B | -2.1146 |
Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-07-13 | Iniziato | Ladenburg Thalmann | Buy |
Nuvectis Pharma Inc Borsa (NVCT) Ultime notizie
Nuvectis Pharma, Inc. (NASDAQ:NVCT) Shares Bought by Baldwin Wealth Partners LLC MA - MarketBeat
How To Trade (NVCT) - Stock Traders Daily
Geode Capital Management LLC Has $501,000 Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World
(NVCT) Proactive Strategies - Stock Traders Daily
Nuvectis Pharma: Still Flat, Although There May Be A Ground Floor Here - Seeking Alpha
Insiders hold 63% of Nuvectis Pharma, Inc. (NASDAQ:NVCT), and they've been buying recently - Yahoo Finance
(NVCT) Long Term Investment Analysis - Stock Traders Daily
Great week for Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders who have 63% stake and they haven’t stopped buying - Simply Wall St
Nuvectis Pharma CEO Ron Bentsur buys $20,925 in shares By Investing.com - Investing.com Australia
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Acquires 4,500 Shares - MarketBeat
Nuvectis Pharma CEO Ron Bentsur buys $20,925 in shares - Investing.com
Nuvectis Pharma stock hits 52-week low at $4.44 amid market challenges - Investing.com Australia
Marlio Charles Mosseri Purchases 17,000 Shares of Nuvectis Pharma, Inc. (NASDAQ:NVCT) Stock - MarketBeat
Nuvectis pharma investor Mosseri-Marlio purchases $79,900 in shares By Investing.com - Investing.com
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium - The Manila Times
NVCT Stock Hits 52-Week Low at $4.61 Amid Market Challenges - Investing.com
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN
Nuvectis Pharma (NVCT) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com Australia
Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges By Investing.com - Investing.com South Africa
Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia
Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St
Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com
Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com
Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News
Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat
Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com Canada
Nuvectis pharma chairman buys $98,400 in common stock - Investing.com
Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance
Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail
500: Something went wrong - Investing.com Canada
Why Is Nuvectis Pharma Stock Trading Lower On Thursday?Nuvectis Pharma (NASDAQ:NVCT) - Benzinga
NVCT stock touches 52-week low at $5.05 amid market fluctuations - Investing.com India
U.S. Stock market: Nuvectis Pharma declined by 40.58% while Sow Good was down by 55.30% during mid day trading - Business Upturn
Nuvectis stock sinks on data for cancer drug (NVCT:NASDAQ) - Seeking Alpha
Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study - MarketWatch
Nuvectis Pharma Inc trading resumes - TipRanks
U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn
Nuvectis Pharma Reports Encouraging NXP800 Interim Data - GlobeNewswire
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase - The Bakersfield Californian
Nuvectis Pharma's NXP800 Shows Promise in Phase 1b Cancer Trial, New Dosing Success | NVCT Stock News - StockTitan
Trading (NVCT) With Integrated Risk Controls - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Announces Third Quarter 2024 Financial Results and Business Updates - Defense World
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):